<DOC>
	<DOCNO>NCT01864200</DOCNO>
	<brief_summary>This study evaluate recovery copperhead snake bite patient mild moderate venom effect . Potential subject receive CroFab antivenom placebo . The trial conduct emergency room doctor , toxicologist , surgeon hospital region copperhead bite common . After blinded treatment discharge , subject return clinic follow-up assessment day 3 , 7 , 14 , 28 snake bite . The subject also call telephone follow-up assessment day 10 , 17 , 24 snake bite . The purpose study compare recovery copperhead snake bite patient treat antivenom versus placebo ( active drug ) measure Patient Specific Functional Scale ( PSFS ) Day 14 follow-up .</brief_summary>
	<brief_title>Randomized , Double-Blind , Placebo-Controlled Study : CroFab® v Placebo Copperhead Snake Envenomation</brief_title>
	<detailed_description />
	<mesh_term>Snake Bites</mesh_term>
	<criteria>Inclusion Criteria Envenomation copperhead snake . Snake identify one follow mean : i.Snake photograph snake brought Emergency Department ii.Patient choose copperhead array snake photograph iii.Patient envenomated area copperhead endemic iv.Patient envenomated captive copperhead snake Completion informed consent eligibility confirmation within 24 hour envenomation Envenomation one extremity , distal elbow knee Clinical evidence mild moderate venom effect ( limb swell and/or tenderness ) present ( Venom effect need progress . ) Patient willing able complete followup schedule assessment Patient able read , comprehend sign IRB approve consent document ( ) Patient able read comprehend write assessment tool ( e.g. , DASH , LEFS , PROMIS Physical Function Short Form 10a ( PROMIS PF10 ) , PGIC , etc . ) Patient ≥12 year age Patient sober , competent , able complete verbal write informed consent Exclusion Criteria Patient clinical evidence severe venom effect define meet one follow parameter : . Swelling entire extremity ( major joint affect ) 1 . Lower extremity : swell cross hip joint 2 . Upper extremity : swell cross shoulder joint ii . INR &gt; 2.0 iii . Platelets &lt; 50,000 cell / µL iv . Fibrinogen &lt; 50 mg/dL v. Compartment syndrome vi . Systolic Blood Pressure &lt; 90 mmHg vii . More minimal bleeding viii . Investigator 's clinical discretion Patient already receive antivenom management current envenomation Patient pregnant breastfeeding Patient prisoner Patient distract injury condition acute pain functional impairment , and/or unable make reliable selfreport functionality status base solely condition interest Patient previous snake envenomation body area 30 day prior screening/enrollment , regardless whether antivenom administer previous envenomation Patient acute traumatic event , surgery , acute medical event , exacerbation preexist medical surgical condition affect envenomated extremity within 30 day prior screening/enrollment Patient participate clinical study involve investigational pharmaceutical product device within 3 month prior screen may impact clinical outcome snakebite Patient previously participate clinical study Patient know history hypersensitivity component CroFab® , papaya papain Patient otherwise unsuitable inclusion study , base opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>